---
title: "Nuvectis Pharma 将在 H.C. Wainwright BioConnect 投资者会议上进行展示"
description: "Nuvectis Pharma 将在 H.C. Wainwright BioConnect 投资者会议上进行演讲\n\nNuvectis Pharma Inc.（纳斯达克代码：NVCT）是一家临床阶段的生物制药公司，将在第三届 H.C. Wainwright 全球 BioConnect 投资者会议上进行演讲。该活动定于 2025 年 5 月 20 日上午 10:30 至 11:00（东部时间）举行。董"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/240641875.md"
published_at: "2025-05-16T20:35:13.000Z"
---

# Nuvectis Pharma 将在 H.C. Wainwright BioConnect 投资者会议上进行展示

> Nuvectis Pharma 将在 H.C. Wainwright BioConnect 投资者会议上进行演讲

Nuvectis Pharma Inc.（纳斯达克代码：NVCT）是一家临床阶段的生物制药公司，将在第三届 H.C. Wainwright 全球 BioConnect 投资者会议上进行演讲。该活动定于 2025 年 5 月 20 日上午 10:30 至 11:00（东部时间）举行。董事长兼首席执行官 Ron Bentsur 将提供有关公司在肿瘤学领域开发创新精准药物的见解

Nuvectis Pharma 将在 H.C. Wainwright BioConnect 投资者会议上进行演讲

Nuvectis Pharma Inc.（纳斯达克代码：NVCT）是一家临床阶段的生物制药公司，将在第三届 H.C. Wainwright 全球 BioConnect 投资者会议上进行演讲。该活动定于 2025 年 5 月 20 日上午 10:30 至 11:00（东部时间）举行。董事长兼首席执行官 Ron Bentsur 将提供关于公司在肿瘤学领域开发创新精准药物的见解。

### Related Stocks

- [NVCT.US - Nuvectis Pharma](https://longbridge.com/zh-CN/quote/NVCT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nuvectis Pharma Launches Phase 1b Trial of NXP900 and Osimertinib in EGFRmut+ NSCLC | Nuvectis Pharma Inc. has initiated a Phase 1b clinical trial to evaluate the combination of NXP900 and osimertinib in EG | [Link](https://longbridge.com/zh-CN/news/270006176.md) |
| Director Matthew L. Kaplan Acquires Common Shares of Nuvectis Pharma Inc | Matthew L. Kaplan, Director of Nuvectis Pharma Inc., has acquired common shares of the company. The full filing is avail | [Link](https://longbridge.com/zh-CN/news/264659938.md) |
| Nuvectis Pharma Hosts Virtual Meeting on NXP900 Phase 1b Program in Advanced Solid Tumors | Nuvectis Pharma Inc. will host a virtual meeting on December 2, 2025, to discuss the NXP900 Phase 1b Program in advanced | [Link](https://longbridge.com/zh-CN/news/267359156.md) |
| Nuvectis Pharma FY2029 EPS Forecast Lifted by Roth Capital | Roth Capital has raised its FY2029 earnings forecast for Nuvectis Pharma (NASDAQ: NVCT) from $3.10 to $3.34 per share. T | [Link](https://longbridge.com/zh-CN/news/264677828.md) |
| Nuvectis Pharma Insider Bought Shares Worth $957,083, According to a Recent SEC Filing | Nuvectis Pharma Insider Bought Shares Worth $957,083, According to a Recent SEC Filing | [Link](https://longbridge.com/zh-CN/news/263285973.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。
